Vertex Pharmaceuticals Inc. (VRTX)

188.07
NASDAQ : Health Technology
Prev Close 185.72
Day Low/High 185.67 / 188.56
52 Wk Low/High 144.07 / 195.81
Avg Volume 1.41M
Exchange NASDAQ
Shares Outstanding 255.17M
Market Cap 47.48B
EPS 8.20
P/E Ratio 22.96
Div & Yield N.A. (N.A)
Positive Phase 3 Study For Tezacaftor/Ivacaftor Combination In Children Aged 6-11 Years With Cystic Fibrosis Supports European Medicines Agency Submission

Positive Phase 3 Study For Tezacaftor/Ivacaftor Combination In Children Aged 6-11 Years With Cystic Fibrosis Supports European Medicines Agency Submission

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the results of a Phase 3 study conducted in Europe and Australia of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis (CF) who have either...

Vertex Reports Full-Year And Fourth-Quarter 2018 Financial Results

Vertex Reports Full-Year And Fourth-Quarter 2018 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year and fourth quarter ended December 31, 2018 and provided full-year 2019 financial guidance.

Health Canada Grants Market Authorization For KALYDECO® (ivacaftor) In Children Ages 12 To <24 Months With Certain Mutations In The CFTR Gene

Health Canada Grants Market Authorization For KALYDECO® (ivacaftor) In Children Ages 12 To <24 Months With Certain Mutations In The CFTR Gene

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Market Authorization for KALYDECO ® (ivacaftor) to include use in children with cystic fibrosis (CF) ages 12 to <24 months who have one of the following...

Merck KGaA, Darmstadt, Germany, Grants Exclusive License To Vertex For Two DNA Damage Response Inhibitors

Merck KGaA, Darmstadt, Germany, Grants Exclusive License To Vertex For Two DNA Damage Response Inhibitors

DARMSTADT, Germany, January 24, 2019 /PRNewswire/ -- Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas    Merck KGaA, Darmstadt, Germany retains...

Vertex Announces Departure Of Ian Smith, Names Interim CFO

Vertex Announces Departure Of Ian Smith, Names Interim CFO

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Ian Smith has been terminated as Chief Operating Officer and interim Chief Financial Officer (CFO) effective immediately.

Vertex To Announce Full-Year And Fourth-Quarter 2018 Financial Results On February 5

Vertex To Announce Full-Year And Fourth-Quarter 2018 Financial Results On February 5

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its full year and fourth quarter 2018 financial results on Tuesday, February 5, 2019 after the financial markets close.

Vertex Announces European Commission Approval For ORKAMBI&reg; (lumacaftor/ivacaftor) For Treatment Of Children With Cystic Fibrosis Aged 2 To 5 Years Old With Most Common Form Of The Disease

Vertex Announces European Commission Approval For ORKAMBI® (lumacaftor/ivacaftor) For Treatment Of Children With Cystic Fibrosis Aged 2 To 5 Years Old With Most Common Form Of The Disease

Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI ® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have...

Vertex And Arbor Biotechnologies Establish Collaboration To Discover Novel Proteins To Advance Discovery Of Gene-Editing Therapies

Vertex And Arbor Biotechnologies Establish Collaboration To Discover Novel Proteins To Advance Discovery Of Gene-Editing Therapies

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Arbor Biotechnologies (Arbor) today announced that the two companies have entered into a strategic research collaboration focused on the discovery of novel proteins including DNA endonucleases to...

Vertex To Present At The J.P. Morgan Healthcare Conference On January 7

Vertex To Present At The J.P. Morgan Healthcare Conference On January 7

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.

Vertex Pharmaceuticals Becomes #35 Most Shorted Nasdaq 100 Component, Replacing Ctrip.com International

Vertex Pharmaceuticals Becomes #35 Most Shorted Nasdaq 100 Component, Replacing Ctrip.com International

The most recent short interest data has been released for the 12/14/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Vertex Announces It Will Submit Cystic Fibrosis Medicines ORKAMBI&reg; (lumacaftor/ivacaftor) As Well As SYMKEVI&reg; (tezacaftor/ivacaftor) To Be Used In Combination With Ivacaftor, To The Scottish Medicines Consortium For Appraisal

Vertex Announces It Will Submit Cystic Fibrosis Medicines ORKAMBI® (lumacaftor/ivacaftor) As Well As SYMKEVI® (tezacaftor/ivacaftor) To Be Used In Combination With Ivacaftor, To The Scottish Medicines Consortium For Appraisal

Vertex Pharmaceuticals (Europe) Limited today announced that, following constructive discussions with the Scottish Government, it will submit ORKAMBI ® (lumacaftor/ivacaftor) as well as SYMKEVI ® (tezacaftor/ivacaftor) to be used in combination with...

Vertex Announces Positive Phase 2 Data In Third Proof-of-Concept Study With The NaV1.8 Inhibitor VX-150

Vertex Announces Positive Phase 2 Data In Third Proof-of-Concept Study With The NaV1.8 Inhibitor VX-150

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results of a Phase 2 study of the investigational NaV1.

Health Canada Grants Market Authorization For ORKAMBI&reg; (lumacaftor/ivacaftor) For Children With Cystic Fibrosis Aged 2 To 5 Years Old With Most Common Form Of The Disease

Health Canada Grants Market Authorization For ORKAMBI® (lumacaftor/ivacaftor) For Children With Cystic Fibrosis Aged 2 To 5 Years Old With Most Common Form Of The Disease

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that Health Canada has granted Market Authorization for ORKAMBI ® (lumacaftor/ivacaftor) to include use in children ages 2 through 5 years with cystic fibrosis (CF) who have two copies of...

Monday Madness: Ready to Add Some Stocks to Your Holiday Wishlist?

Monday Madness: Ready to Add Some Stocks to Your Holiday Wishlist?

Here's what you're missing on TheStreet.

Top Analysts: Five 'Strong Buy' Stocks for 2019

Top Analysts: Five 'Strong Buy' Stocks for 2019

These 5 hot stocks will deliver outsized gains in 2019, say best-performing analysts

Vertex Announces European Commission Approval For KALYDECO&reg; (ivacaftor) To Treat Patients With Cystic Fibrosis Aged 12 To &lt;24 Months With Certain Mutations In The CFTR Gene

Vertex Announces European Commission Approval For KALYDECO® (ivacaftor) To Treat Patients With Cystic Fibrosis Aged 12 To <24 Months With Certain Mutations In The CFTR Gene

Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for KALYDECO ® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at...

Vertex Pharmaceuticals Becomes #45 Most Shorted Nasdaq 100 Component, Replacing Intuit

Vertex Pharmaceuticals Becomes #45 Most Shorted Nasdaq 100 Component, Replacing Intuit

The most recent short interest data has been released for the 11/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Two Phase 3 Studies Of The Triple Combination Of VX-659, Tezacaftor And Ivacaftor Met Primary Endpoint Of Improvement In Lung Function (ppFEV1) In People With Cystic Fibrosis

Two Phase 3 Studies Of The Triple Combination Of VX-659, Tezacaftor And Ivacaftor Met Primary Endpoint Of Improvement In Lung Function (ppFEV1) In People With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that treatment with the triple combination of the next-generation corrector VX-659, tezacaftor and ivacaftor resulted in statistically significant improvements in lung function (percent...

Vertex Receives European CHMP Positive Opinion For ORKAMBI&reg; (lumacaftor/ivacaftor) For Treatment Of Children With Cystic Fibrosis Aged 2 To 5 Years Old With Most Common Form Of The Disease

Vertex Receives European CHMP Positive Opinion For ORKAMBI® (lumacaftor/ivacaftor) For Treatment Of Children With Cystic Fibrosis Aged 2 To 5 Years Old With Most Common Form Of The Disease

Vertex Pharmaceuticals (Europe) Limited today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ORKAMBI ® (lumacaftor/ivacaftor) for the treatment of people with...

Vertex Pharmaceuticals Achieves #43 Analyst Rank, Surpassing NRG Energy

Vertex Pharmaceuticals Achieves #43 Analyst Rank, Surpassing NRG Energy

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Vertex Pharmaceuticals, Inc. has taken over the #43 spot from NRG Energy Inc , according to ETF Channel.

Vertex Announces European Authorization For Third Cystic Fibrosis Medicine SYMKEVI&reg; (tezacaftor/ivacaftor), To Be Used In Combination With Ivacaftor (KALYDECO&reg;), For People With CF Aged 12 And Older With Certain Mutations In The CFTR Gene

Vertex Announces European Authorization For Third Cystic Fibrosis Medicine SYMKEVI® (tezacaftor/ivacaftor), To Be Used In Combination With Ivacaftor (KALYDECO®), For People With CF Aged 12 And Older With Certain Mutations In The CFTR Gene

Vertex Pharmaceuticals (Europe) Limited, today announced that the European Commission has granted Marketing Authorization for SYMKEVI ® (tezacaftor/ivacaftor) in a combination regimen with ivacaftor (KALYDECO ®) for the treatment of people with cystic...

Why Investors Should Favor Smaller Biotech Companies

Why Investors Should Favor Smaller Biotech Companies

Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.

Vertex Reports Third-Quarter 2018 Financial Results

Vertex Reports Third-Quarter 2018 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2018 and reviewed recent progress with its approved and investigational medicines.

Vertex Receives European CHMP Positive Opinion For KALYDECO&reg; (ivacaftor) To Treat Patients With Cystic Fibrosis Aged 12 To &lt;24 Months With Certain Mutations In The CFTR Gene

Vertex Receives European CHMP Positive Opinion For KALYDECO® (ivacaftor) To Treat Patients With Cystic Fibrosis Aged 12 To <24 Months With Certain Mutations In The CFTR Gene

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO ® (ivacaftor) to include the treatment of people with cystic...

Vertex Data Presented At North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding And Enhancing Options For Treating The Underlying Cause Of Cystic Fibrosis

Vertex Data Presented At North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding And Enhancing Options For Treating The Underlying Cause Of Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that eight scientific abstracts from the company's portfolio of cystic fibrosis (CF) medicines are being presented at the 32 nd North American Cystic Fibrosis Conference taking place...

Vertex To Announce Third Quarter 2018 Financial Results On October 24

Vertex To Announce Third Quarter 2018 Financial Results On October 24

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2018 financial results on Wednesday, October 24, 2018 after the financial markets close.

Chart of the Day: Vertex Pharmaceuticals

VRTX is still clinging to the pattern of higher lows.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Vertex To Present At The Morgan Stanley Healthcare Conference On September 14

Vertex To Present At The Morgan Stanley Healthcare Conference On September 14

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Friday, September 14, 2018 at 12:15 p.

Vertex Appoints Katharine Jensen As Head Of Corporate Social Responsibility

Vertex Appoints Katharine Jensen As Head Of Corporate Social Responsibility

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Katharine Jensen has been appointed Head of Corporate Social Responsibility (CSR).

TheStreet Quant Rating: A (Buy)